Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Selective embolization of a ruptured splenic artery aneurysm after a cesarean section at 32 weeks of gestation].

Gynecologie, obstetrique, fertilite & senologie·2020

Same author

Functional implications of novel ADAM10 mutations in reticulate acropigmentation of Kitamura.

The British journal of dermatology·2017

Same author

Expectant management and laser photocoagulation in isolated selective intra-uterine growth restriction: A single-center series.

Journal of gynecology obstetrics and human reproduction·2017

Same author

[Maternal morbidity and mortality associated with conservative management for placenta morbidly adherent (accreta) diagnosed during pregnancy. Report of 15 cases].

Journal de gynecologie, obstetrique et biologie de la reproduction·2016

Same author

[Management of pregnancy complicated by Eisenmenger syndrome: Modalities of success].

Gynecologie, obstetrique & fertilite·2016

Same author

[Accuracy of placenta accreta prenatal diagnosis by ultrasound and MRI in a high-risk population].

Journal de gynecologie, obstetrique et biologie de la reproduction·2015

Search research articles

Related Experiment Video

Updated: Jun 22, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Targeting the mevalonate pathway for improved anticancer therapy.

¹Department of Toxicology, University of Mainz, Obere Zahlbacher Str. 67, D-55131 Mainz, Germany. fritz@uni-mainz.de

Current Cancer Drug Targets

|June 11, 2009

Summary

The mevalonate pathway generates isoprene units crucial for cell functions and protein prenylation. Inhibiting this pathway offers potential cancer treatment strategies by disrupting Ras/Rho protein signaling.

Related Experiment Videos

Last Updated: Jun 22, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Area of Science:

Biochemistry
Molecular Biology
Oncology

Background:

The mevalonate pathway is vital for producing isoprene moieties.
Isoprene precursors are essential for membrane integrity, steroid synthesis, and cell respiration.
Isoprene precursors are also required for prenylation of regulatory proteins like Ras and Ras-homologous (Rho) GTPases.

Purpose of the Study:

To summarize and discuss the advantages and disadvantages of using compounds that inhibit the mevalonate pathway for cancer treatment.
To explore the impact of mevalonate pathway inhibition on Ras/Rho protein functions and signaling.

Main Methods:

Literature review and synthesis of existing research on the mevalonate pathway and its inhibitors.
Analysis of the roles of Ras/Rho proteins in cellular processes and cancer progression.
Evaluation of the therapeutic potential and challenges of targeting the mevalonate pathway in oncology.

Main Results:

The mevalonate pathway's role in generating essential biomolecules and facilitating protein prenylation is confirmed.
Ras/Rho proteins, crucial for signal transduction, rely on lipid modification (prenylation) for their function.
Inhibition of the mevalonate pathway impacts Ras/Rho protein localization and function, affecting cell proliferation, tumor progression, and cell death.

Conclusions:

Pharmacological inhibition of the mevalonate pathway presents a potential therapeutic strategy for cancer by disrupting critical signaling pathways.
Understanding the pros and cons of targeting this pathway is essential for developing effective and safe anticancer treatments.
Further research is needed to optimize the use of mevalonate pathway inhibitors in clinical oncology.